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Objectives: To estimate medical expenditure for people with diabetes covered 
by Urban Employee Basic Medical Insurance (UEBMI) in Fujian. MethOds: Claims 
data were extracted from UEBMIF database during 2012.1. 1 to 2012.12.31. People 
with diabetes were identified by keyword – diabetes. To estimate expenditures, we 
used Sum_All Medical method. Descriptive analyses were conducted by using EXCEL 
2010. Results: In 2012, one of the Fujian UEBMI database recorded claims data of 
240079 patients, including 5953 with diabetes (2.48%), among which 68.81% were male 
and 91.03% were age over 50. The number of General Outpatient (GO)/Catastrophic 
Outpatient (CO)/inpatient with diabetes was 5196/4964/2325. GO/CO with diabetes 
visited physicians averagely 24.13/46.02 times, almost 60% of the visits happened in 
tertiary hospitals. People with diabetes each used inpatient services 1.70 times; the 
mean number of LOS was 16.52 days. Total Direct Medical Expenditure for people with 
Diabetes (TDMED) was CNY 132 million (16.33% of total direct medical expenditure); 
out-of-pocket spending accounted for 27.20%. GO/CO/inpatient medical expenditures 
were CNY 3824.16/7960.88/31365.25 per person and CNY 158.49/172.97/18396.62 per 
visit. Expenses for medicine was CNY 89 million (67.01% of TDMED), only CNY 17 mil-
lion (13.03% of TDMED) was spent on anti-glycaemic medicine. 94.56% of people with 
diabetes took prescribed anti-glycaemic medicine, including OAD (88.34%), insulin 
(41.21%) and traditional Chinese medicine (23.13%). For CO, 47.26% of the visits were 
due to diabetes and the medical expenditure accounted for 43.40%. Among hospi-
talized people with diabetes, only 10.68% of their primary diagnoses were diabetes. 
Inpatient with diabetes whose primary diagnoses were diabetes consumed less health 
care resources (average LOS/medical expenditure per person/medical expenditure 
per visit) than those whose primary diagnoses were diabetic complications or other 
diseases (15.47days/CNY 14567.57/CNY 12481.90 vs. 16.65days/CNY 27666.67/CNY 
19161.66). cOnclusiOns: Diabetes, as one of the major chronic diseases, consumed 
a large amount of medical resources in Fujian. Majority of direct medical expenditure 
were spent on treating diabetic complications and other diseases.
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Objectives: The aim of this study was to assess the indirect costs associated with 
types 1 and 2 diabetes mellitus (DM) from the perspective of the Social Insurance 
Institution (ZUS) in Poland. MethOds: The estimates were based on data from the 
year 2012 concerning absence from work due to the illness (sick leave) the amount 
of short term disability, the sufferers of which claim rehabilitation benefit, and the 
amount of permanent (or long term) disability, the sufferers of which claim dis-
ability pension. Costs were presented in Polish zloty (PLN). Results: Total indirect 
costs of DM types 1 and type 2 in the year 2012 in Poland were 59 013 912 PLN and 
66 597 701 PLN, respectively. The highest component of indirect costs of DM type 1 
was sick leave (61%). Long and short term disability costs constitute 28% and 11% 
of total indirect costs of DM type 1, respectively. A slightly different situation was 
reported in the case of type 2 diabetes: long term disability costs were only 1% of 
total indirect costs, and short term disability had a slightly larger part of indirect 
costs (less than 5%). The highest component of indirect costs of DM type 2 was sick 
leave (95%). One sick leave of a person with types 1 or 2 diabetes generated a cost 
of lost productivity equal to 1 771 PLN or 1 585 PLN, respectively. The cost of dis-
ability pension per one person was higher than rehabilitation benefit, and equalled 
41 398 PLN compared with 17 249 PLN (the average value of one short and long 
term benefit payment was the same for both types of diabetes). cOnclusiOns: 
DM in Poland generated high indirect costs. The main component was sick leave; 
rehabilitation benefit and disability pension generated much lower costs for Social 
Insurance Institution.
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Objectives: Type 2 Diabetes Mellitus (T2DM) is a worldwide prevalent chronic 
disease, related to high morbidity and mortality, and to significant socioeconomic 
costs. However, the magnitude of cost varies significantly among empirical studies. 
The objective of this literature review is to identify the main drivers that influ-
ence the costs of T2DM. MethOds: We searched relevant databases for studies 
estimating T2DM costs, published in English and Spanish in the USA and Europe 
(1995-2014). Search terms included “diabetes”, “costs”, “burden”, and “economic 
impact”. No exclusion was made based on study design. Cost drivers and differences 
in methodologies across studies were identified. Results: A total of 25 papers 
were included out of 618 relevant titles identified. Costing methodologies and cost 
drivers vary significantly causing important variations in results. The main differ-
ence in methodology refers to estimating T2DM costs versus the costs of people 
living with T2DM, which include all direct sanitary costs -whether directly related 
to T2DM or not- and may increase total costs by up to 74%. Direct sanitary costs 
range between 40% and 75% of total costs depending partially on whether produc-
tivity losses and caregiving are considered. The relative weight of hospitalizations 
range between 20% and 60% of sanitary costs depending on the categories included. 
Pharmacologic costs range between 13% and 46%, which include antidiabetic drugs 
and treatments for complications derived from poor control. Optimal glycemic con-
trol reduces costs but is not always considered in the studies. Microvascular and/
or macrovascular complications and hypoglycemic events increase total cost per 
patient. cOnclusiOns: Differences in costing methodology, the type of cost cat-
egories included in the analysis and the source of data greatly influence the results 
of the studies and impede reaching accurate conclusions regarding the cost of T2DM. 
Designing standardized costing methodology guidelines would help future studies 
estimate the real burden of T2DM.
Objectives: To determine the clinical (compliance, metabolic control, hypoglycae-
mia and cardiovascular events [CVE]) and economic (resources and costs) impact 
of metformin in combination with dipeptidyl peptidase-4 inhibitors (DPP4-I) or 
sulfonylureas in patients with type 2 diabetes. MethOds: Design: Multicentre, 
observational retrospective study. Patients aged ≥ 30 years under treatment with 
metformin who initiated a second oral antidiabetic treatment in 2008-2009 were 
evaluated. Two study groups were established: a) metformin + DPP4-I, b) met-
formin + sulfonylureas. Main measures: comorbidity, metabolic control (HbA1c < 
7%), compliance and complications (hypoglycaemia, CVE). Patients were followed 
for 2 years. The cost model considered direct (primary/specialised care) and indi-
rect (productivity) health care costs. Statistical analysis: logistic regression models 
and ANCOVA, p < 0.05. Results: We recruited 1,405 patients (men age 67.1 years, 
56.2% male) of whom 37% initiated a second treatment with DPP4-I and 63% with 
sulfonylureas. At 2 years follow-up, patients treated with DPP4-I showed better 
compliance (70.3% vs 60.6%), better metabolic control (64.3% vs 60.6%), and a lower 
proportion of hypoglycaemia (13.9% vs 40.4%) (p < 0.05). The mean unit costs of the 
total adjusted costs were € 2,341 vs € 2,512, respectively; p = 0.038. Rates of CVE 
and renal failure were 3.7% vs 6.4%; p = 0.027. Vildagliptin was the most commonly 
used DPP4-I. cOnclusiOns: Sulfonylureas were the most frequently used drugs 
for the treatment of diabetes. Patients treated with DPP4-I had better compliance 
and control of diabetes, with lower rates of hypoglycaemia and CVE, resulting in 
reduced health care costs.
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Objectives: To estimate the impact of diabetic complications on immediate and 
long-term direct medical costs in Hong Kong. MethOds: A retrospective cohort 
study was conducted among 137,634 diabetic subjects from a territory-wide admin-
istrative database over six years (2008-2013). The trends of annual direct medi-
cal costs were analyzed by three groups: group 1) subjects without complications 
over study period; group 2) subjects with existing complications at baseline; and 
group 3) subjects developing new complications during follow-up. We employed 
panel data regression to investigate the impact of each diabetic complication on 
direct medical costs in the event year and subsequent years, adjusting for age and 
Charlson Comorbidity Score. Results: We found 10,322 subjects with existing 
diabetic complications at baseline (January 1st, 2009), and 14,349 newly developed 
diabetic complications over 5 years. The annual direct medical costs increased from 
$US4,629 to $US15,585 in the new complications group, which is substantially higher 
than the modest rise in the no complication group (from $US1,157 to $US1,984). The 
annual direct medical cost of baseline case was $US1,062 (62 year-old, no compli-
cation, Charlson Comorbidity Score= 0). After adjusting for age and comorbidity, 
compared to the baseline case, the multipliers of annual direct medical costs in 
the event year were: acute myocardial infarction (AMI) 10.61; other ischemic heart 
disease (IHD) 3.67; congestive heart failure (CHF) 8.46; stroke 10.17; sight threaten-
ing diabetic retinopathy (STDR) 3.41; blindness 2.78; end stage renal disease (ESRD) 
12.16; peripheral vascular disease (PVD) 3.00; amputation: 3.48. The multipliers in 
subsequent years were: AMI 1.45; other IHD 1.32; CHF 1.86; stroke 1.37; STDR 2.16; 
blind 1.32; ESRD 1.86; PVD 1.42; amputation 1.32. cOnclusiOns:  There were wide 
variations in direct medical cost in event year and subsequent years across differ-
ent major complications. These data would be useful for economic evaluations of 
diabetes prevention or treatment programs.
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Objectives: This study aimed to analyze the direct medical cost of diabetes related 
micro- and macrovascular complications in Korean people with diabetes melli-
tus. MethOds: Using the Health Insurance Review & Assessment Service-National 
Patients Sample (about 1.3 million patients), which was a stratified sampling from 
the entire population (about 46 million persons) under the Korean national health 
security system (2011), estimation of direct medical cost complication for patients 
who have diabetes related chronic complications were performed. We used the 
6th revision of Korean Standard Classification of Diseases (KCD-6) which had been 
developed with the reference of the 10th version of International Classification (ICD-
10). All statistical analyses were performed using the Statistical Analysis System 
(SAS, version 9.3). Results: The mean age of the subjects was 61.4 years, 52.1% were 
male and 47.9% were female. Of the 91,463 patients with DM, 20,584 patients (22%) 
had at least one microvascular or macrovascular complication, 70,879 patients (78%) 
had no complication. The average annual direct medical cost in patients who had 
no complications was 351,660 won in 2011. The average annual direct medical cost 
in patients who had microvascular complications such as retinopathy, nephropathy, 
neuropathy was 506,160 won, 1.4 times higher than without DM complications, who 
had macrovascular complications such as MI, CVA, ESRD was 1,362,928 won, 3.8 
times higher than without DM complications. cOnclusiOns: Diabetic complica-
tions have a substantial impact on the direct medical costs of DM patients. As the 
number of people with diabetes continues to rise, early detection of the disease and 
implementation of timely and appropriate therapeutic strategies could decrease 
the burden of diabetes chronic complications and also huge related expenditures.
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